Company: VMCWF
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023515
Chunk: 6

Company: Valuence Merger Corp. I
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 6
---
(47,827) 
     242,387 
  
    Net cash used in operating activities 
     (338,888) 
     (694,222)

    Cash Flows from Investing Activities: 

    Investment of cash into Trust Account 
     (224,088) 
     (700,055)
  
    Cash withdrawn from Trust Account in connection with redemption 
     —  
     49,900,380 
  
    Net cash (used in) provided by investing activities 
     (224,088) 
     49,200,325 

    Cash Flows from Financing Activities: 

    Proceeds from convertible promissory note - related party 
     —  
     300,000 
  
    Advance from related party 
     545,075  
     425,000 
  
    Redemption of ordinary shares 
     —  
     (49,900,380)
  
    Net cash provided by (used in) financing activities 
     545,075  
     (49,175,380)

    Net Change in Cash 
     (17,901) 
     (669,277)
  
    Cash – Beginning of period 
     61,037  
     684,816 
  
    Cash – End of period 
    $43,136  
    $15,539 

The
accompanying notes are an integral part of these unaudited condensed financial statements.

4

VALUENCE
MERGER CORP. I

NOTES
TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

SEPTEMBER
30, 2025

NOTE
1- DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS

Valuence
Merger Corp. I (the “Company”) is a blank check company incorporated as a Cayman Islands exempted company on August 27, 2021.
The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization
or similar business combination with one or more businesses or entities (a “Business Combination”).

The
Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. However, the Company intends
to concentrate its efforts in identifying a potential Business Combination partner that is based in Asia (excluding China, Hong Kong
and Macau) and who is developing breakthrough technology in life sciences and/or advancing